Details
Stereochemistry | ACHIRAL |
Molecular Formula | CH4N2O2 |
Molecular Weight | 76.0547 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
NC(=O)NO
InChI
InChIKey=VSNHCAURESNICA-UHFFFAOYSA-N
InChI=1S/CH4N2O2/c2-1(4)3-5/h5H,(H3,2,3,4)
Hydroxyurea is an oral antimetabolite; inhibits ribonucleotide reductase and DNA synthesis. It is used for resistant chronic myeloid leukemia, locally advanced squamous cell carcinomas of the head and neck (excluding lip) in combination with concurrent chemoradiation, and to reduce the frequency of painful crises and the need for blood transfusions in patients with sickle cell anemia with recurrent moderate to severe painful crises. Hydroxyurea, a myelosuppressive agent, is the only effective drug proven to reduce the frequency of painful episodes. It raises the level of HbF and the haemoglobin level. It usually decreases the rate of painful episodes by 50%. It was first tested in sickle cell disease in 1984. It also decreases the rate of ACS episodes and blood transfusions by ~50 % in adults. It was developed as an anticancer drug and has been used to treat myeloproliferative syndromes-leukemia, melanoma, and ovarian cancer. It was approved for use by FDA in adults. Side effects includes neutropenia, bone marrow suppression, elevation of hepatic enzymes, anorexia, nausea, vomiting and infertility.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL3301398 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | DROXIA Approved UseDROXIA is an antimetabolite indicated to reduce the frequency of painful crises and to reduce the need for blood transfusions in patients with sickle cell anemia with recurrent moderate to severe painful crises Launch Date-6.53184E10 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
793.75 μM EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9473217 |
2000 mg single, oral dose: 2000 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROXYUREA plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3934 μM × h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9473217 |
2000 mg single, oral dose: 2000 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROXYUREA plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
3.32 h EXPERIMENT https://www.ncbi.nlm.nih.gov/pubmed/9473217 |
2000 mg single, oral dose: 2000 mg route of administration: Oral experiment type: SINGLE co-administered: |
HYDROXYUREA plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
Doses
Dose | Population | Adverse events |
---|---|---|
40 mg/kg 2 times / day single, oral Highest studied dose Dose: 40 mg/kg, 2 times / day Route: oral Route: single Dose: 40 mg/kg, 2 times / day Sources: |
unhealthy, 2-18 years n = 10 Health Status: unhealthy Condition: allogeneic transplantation Age Group: 2-18 years Population Size: 10 Sources: |
|
26.7 mg/kg 1 times / day multiple, oral MTD Dose: 26.7 mg/kg, 1 times / day Route: oral Route: multiple Dose: 26.7 mg/kg, 1 times / day Sources: |
unhealthy, 2-18 years Health Status: unhealthy Condition: sickle cell anemia Age Group: 2-18 years Sources: |
|
20 mg/kg 1 times / day multiple, oral Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg, 1 times / day Sources: |
unhealthy, 2-18 years Health Status: unhealthy Age Group: 2-18 years Sources: |
Other AEs: Myelosuppression... Other AEs: Myelosuppression Sources: |
20 mg/kg 1 times / day steady, oral Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: |
unhealthy n = 104 Health Status: unhealthy Condition: Malaria Population Size: 104 Sources: |
Other AEs: Sudden death, Thrombocytopenia... Other AEs: Sudden death (serious, 1 patient) Sources: Thrombocytopenia (below serious, 11 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Myelosuppression | 20 mg/kg 1 times / day multiple, oral Recommended Dose: 20 mg/kg, 1 times / day Route: oral Route: multiple Dose: 20 mg/kg, 1 times / day Sources: |
unhealthy, 2-18 years Health Status: unhealthy Age Group: 2-18 years Sources: |
|
Thrombocytopenia | below serious, 11 patient | 20 mg/kg 1 times / day steady, oral Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: |
unhealthy n = 104 Health Status: unhealthy Condition: Malaria Population Size: 104 Sources: |
Sudden death | serious, 1 patient | 20 mg/kg 1 times / day steady, oral Dose: 20 mg/kg, 1 times / day Route: oral Route: steady Dose: 20 mg/kg, 1 times / day Sources: |
unhealthy n = 104 Health Status: unhealthy Condition: Malaria Population Size: 104 Sources: |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
likely [IC50 >10 uM] | yes (pharmacogenomic study) Comment: Of the 73 children completing the study, 42 had reduced-functioning alleles; 82% of the 27 children taking hydoxyurea had reduced-functioning alleles, versus 47% of 36 those with mild disease (P < .05). |
|||
no [Activation 39.8107 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >10 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no [IC50 >133 uM] | ||||
no | ||||
no | ||||
yes | ||||
yes | ||||
yes |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
no | ||||
weak | ||||
weak | ||||
weak | ||||
weak | ||||
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
PubMed
Title | Date | PubMed |
---|---|---|
Hydroxyurea-induced neurotoxicity in HIV disease. | 1999 Aug 20 |
|
Dibutyryl cyclic AMP-induced enhancement of RB protein degradation in human hepatoma cells. | 1999 Nov-Dec |
|
Senescence-like changes induced by hydroxyurea in human diploid fibroblasts. | 2000 Aug |
|
Ser45 plays an important role in managing both the equilibrium and transition state energetics of the streptavidin-biotin system. | 2000 May |
|
Synergistic inhibition of HIV-1 in activated and resting peripheral blood mononuclear cells, monocyte-derived macrophages, and selected drug-resistant isolates with nucleoside analogues combined with a natural product, resveratrol. | 2000 Nov 1 |
|
[Low-dose cytosine-arabinoside (Ara-C) therapy for chronic myeloid leukemia]. | 2001 |
|
Systematic review of combination antiretroviral therapy with didanosine plus hydroxyurea: a partial solution to Africa's HIV/AIDS problem? | 2001 |
|
Hydroxyurea-induced oxidative damage of normal and sickle cell hemoglobins in vitro: amelioration by radical scavengers. | 2001 |
|
Stroke prevention and treatment in sickle cell disease. | 2001 Apr |
|
Chromosomal aberrations in lymphocytes of employees in transformer and generator production exposed to electromagnetic fields and mineral oil. | 2001 Apr |
|
The anti-malarial artesunate is also active against cancer. | 2001 Apr |
|
A new molecular role for iron in regulation of cell cycling and differentiation of HL-60 human leukemia cells: iron is required for transcription of p21(WAF1/CIP1) in cells induced by phorbol myristate acetate. | 2001 Apr |
|
The Saccharomyces cerevisiae phosphotyrosyl phosphatase activator proteins are required for a subset of the functions disrupted by protein phosphatase 2A mutations. | 2001 Apr 1 |
|
Cell cycle expression of histone genes in Trypanosoma cruzi. | 2001 Apr 6 |
|
Induction of unscheduled DNA synthesis in hairless mouse epidermis by 8-methoxypsoralen plus ultraviolet A (PUVA). | 2001 Feb |
|
Foraging behaviour in Drosophila larvae: mushroom body ablation. | 2001 Feb |
|
Sickle cell anemia and antisickling agents then and now. | 2001 Feb |
|
Role of nitric oxide in the synthesis of guanidinosuccinic acid, an activator of the N-methyl-D-aspartate receptor. | 2001 Feb |
|
Leukotriene modifiers in pediatric asthma management. | 2001 Feb |
|
Dynamic changes in subnuclear NP95 location during the cell cycle and its spatial relationship with DNA replication foci. | 2001 Feb 15 |
|
A novel genetic screen identifies checkpoint-defective alleles of Schizosaccharomyces pombe chk1. | 2001 Jan |
|
Modulation of ara-CTP levels by fludarabine and hydroxyurea in leukemic cells. | 2001 Jan |
|
Chronic neutrophilic leukemia (CNL): a clinical, pathologic and cytogenetic study. | 2001 Jan |
|
Current management in polycythemia vera. | 2001 Jan |
|
Predominantly BCR-ABL negative myeloid precursors in interferon-alpha treated chronic myelogenous leukemia: a follow-up study of peripheral blood colony-forming cells with fluorescence in situ hybridization. | 2001 Jan |
|
Effects of amifostine in a patient with an advanced-stage myelodysplastic syndrome. | 2001 Jan |
|
Inhibition of hepatitis B virus production associated with high levels of intracellular viral DNA intermediates in iron-depleted HepG2.2.15 cells. | 2001 Jan |
|
Cell division activity during apical hook development. | 2001 Jan |
|
Requirement for three novel protein complexes in the absence of the Sgs1 DNA helicase in Saccharomyces cerevisiae. | 2001 Jan |
|
Relative resistance in the development of T cell anergy in CD4+ T cells from simian immunodeficiency virus disease-resistant sooty mangabeys. | 2001 Jan 1 |
|
De novo activation of the beta-phaseolin promoter by phosphatase or protein synthesis inhibitors. | 2001 Jan 19 |
|
[Hydroxyurea--is it a harmless drug in Vaquez disease?]]. | 2001 Mar |
|
Prognostic factors and current practice in treatment of myelofibrosis with myeloid metaplasia: an update anno 2000. | 2001 Mar |
|
Myeloproliferative syndromes. Current opinions from the European Hematology Association Working Group on Myeloproliferative Disorders. | 2001 Mar |
|
Clinical predictors of health-related quality of life depend on asthma severity. | 2001 Mar |
|
Limbal stem cell deficiency arising from systemic chemotherapy. | 2001 Mar |
|
Prognostic impact of bone marrow erythropoietic precursor cells and myelofibrosis at diagnosis of Ph1+ chronic myelogenous leukaemia--a multicentre study on 495 patients. | 2001 Mar |
|
The Saccharomyces cerevisiae MUM2 gene interacts with the DNA replication machinery and is required for meiotic levels of double strand breaks. | 2001 Mar |
|
Synergistic activity of the new ABL-specific tyrosine kinase inhibitor STI571 and chemotherapeutic drugs on BCR-ABL-positive chronic myelogenous leukemia cells. | 2001 Mar |
|
A unique, complex variant philadelphia chromosome translocation in a patient with typical chronic myelogenous leukemia. | 2001 Mar |
|
Osteoclast differentiation factor modulates cell cycle machinery and causes a delay in s phase progression in RAW264 cells. | 2001 Mar 23 |
|
N-Aminoindoline derivatives as inhibitors of 5-lipoxygenase. | 2001 Mar 26 |
|
Incidence of pancreatitis in HIV-infected patients receiving nucleoside reverse transcriptase inhibitor drugs. | 2001 Mar 30 |
|
The BARD1-CstF-50 interaction links mRNA 3' end formation to DNA damage and tumor suppression. | 2001 Mar 9 |
|
Involvement of pRB-related p107 protein in the inhibition of S phase progression in response to genotoxic stress. | 2001 May 18 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.drugs.com/dosage/hydroxyurea.html
Usual Adult Dose for Chronic Myelogenous Leukemia
15 mg/kg/day orally as a single dose
Usual Adult Dose for Head and Neck Cancer
15 mg/kg/day orally as a single dose
Usual Adult Dose for Sickle Cell Anemia
15 mg/kg orally once a day; increase 5 mg/kg/day every 12 weeks
Maximum dose: 35 mg/kg/day
Usual Pediatric Dose for Sickle Cell Anemia
2 years and older:
20 mg/kg orally once a day; increase 5 mg/kg/day every 8 weeks or if a painful crisis occurs; increase dosing only if blood counts are in the acceptable range; do not increase dosing if myelosuppression occurs; if blood counts are considered toxic, discontinue therapy until hematologic recovery
Duration of therapy: Give until mild myelosuppression (absolute neutrophil count 2000/microliter to 4000/microliter) is achieved, up to 35 mg/kg/day
Maximum dose: 35 mg/kg/day
Route of Administration:
Oral
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ESSENTIAL MEDICINES LIST |
8.2
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
||
|
WHO-ATC |
L01XX05
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
||
|
FDA ORPHAN DRUG |
202605
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
||
|
WHO-ESSENTIAL MEDICINES LIST |
10.3
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
||
|
FDA ORPHAN DRUG |
555116
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
||
|
NCI_THESAURUS |
C2150
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
||
|
NDF-RT |
N0000006999
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
||
|
LIVERTOX |
NBK548724
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
||
|
FDA ORPHAN DRUG |
463414
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
||
|
NDF-RT |
N0000180853
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
||
|
EU-Orphan Drug |
EU/3/03/154
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
||
|
NCI_THESAURUS |
C272
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
||
|
EMA ASSESSMENT REPORTS |
SIKLOS (AUTHORIZED: ANEMIA, SICKLE-CELL)
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
||
|
FDA ORPHAN DRUG |
400413
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
||
|
FDA ORPHAN DRUG |
49590
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
||
|
WHO-VATC |
QL01XX05
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
44423
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
PRIMARY | |||
|
5552
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
PRIMARY | RxNorm | ||
|
204-821-7
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
PRIMARY | |||
|
Hydroxyurea
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
PRIMARY | |||
|
6887
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
PRIMARY | |||
|
DB01005
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
PRIMARY | |||
|
127-07-1
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
PRIMARY | |||
|
32065
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
PRIMARY | |||
|
1991
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
PRIMARY | |||
|
C560
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
PRIMARY | |||
|
D006918
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
PRIMARY | |||
|
HYDROXYCARBAMIDE
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
PRIMARY | |||
|
SUB08076MIG
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
PRIMARY | |||
|
CHEMBL467
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
PRIMARY | |||
|
X6Q56QN5QC
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
PRIMARY | |||
|
3657
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
PRIMARY | |||
|
M6158
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
PRIMARY | Merck Index | ||
|
DTXSID6025438
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
PRIMARY | |||
|
1399
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
PRIMARY | |||
|
6822
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
PRIMARY | |||
|
X6Q56QN5QC
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
PRIMARY | |||
|
1332000
Created by
admin on Fri Dec 16 16:16:14 UTC 2022 , Edited by admin on Fri Dec 16 16:16:14 UTC 2022
|
PRIMARY |
ACTIVE MOIETY